{"entity":{"id":"paper-keynote-775-nejm-2022","kind":"paper","name":"KEYNOTE-775: lenvatinib plus pembrolizumab versus chemotherapy for previously treated advanced endometrial cancer","aka":[],"tldr":"After platinum chemotherapy, the combination of the kinase inhibitor lenvatinib and pembrolizumab lengthened survival compared with doxorubicin or paclitaxel in advanced endometrial cancer, including in the mismatch repair-proficient majority.","summary":"Phase 3 trial of 827 patients with advanced endometrial cancer after one prior platinum regimen randomised to lenvatinib plus pembrolizumab or physician's choice of doxorubicin or weekly paclitaxel.\n\nIn mismatch repair-proficient disease median overall survival was 17.4 versus 12.0 months (hazard ratio 0.68) and median progression-free survival 6.6 versus 3.8 months; results were similar in the whole population. Grade 3 or higher adverse events occurred in 89 percent of the combination arm.","asOf":"2026-09-17","links":[{"label":"N Engl J Med 2022","url":"https://doi.org/10.1056/NEJMoa2108330"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/35045221/"}],"tags":[],"related":[],"cancers":["advanced-recurrent-endometrial-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["lenvatinib","pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["keynote-775"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nejm"],"dependsOn":[],"notes":[],"journal":"New England Journal of Medicine","year":2022,"doi":"10.1056/NEJMoa2108330","pmid":"35045221","authors":"Makker V, Colombo N, Casado Herráez A, et al.","paperType":"rct","findings":["Mismatch repair-proficient: median overall survival 17.4 vs 12.0 months; hazard ratio 0.68.","All patients: median overall survival 18.3 vs 11.4 months; hazard ratio 0.62."],"whatItMeans":"Lenvatinib-pembrolizumab is the standard second-line treatment for mismatch repair-proficient endometrial cancer after platinum, though its toxicity is considerable and its place after first-line immunotherapy is unclear.","caveats":["Hypertension, hypothyroidism, diarrhoea and weight loss led to frequent dose reductions.","Patients had not received prior immunotherapy, unlike many today."],"changedPractice":true,"participants":827},"route":"/key-papers/paper-keynote-775-nejm-2022/","neighbours":{"cancer":[{"id":"advanced-recurrent-endometrial-cancer","kind":"cancer","name":"Advanced or recurrent endometrial cancer","route":"/cancers/advanced-recurrent-endometrial-cancer/"}],"drug":[{"id":"lenvatinib","kind":"drug","name":"Lenvatinib","route":"/drugs/lenvatinib/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"trial":[{"id":"keynote-775","kind":"trial","name":"KEYNOTE-775 / Study 309","route":"/trials/keynote-775/"}],"journal":[{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/"}]}}